JPD:GBA帕金森病患者,体位性低血压明显

2022-05-19 Freeman MedSci原创

GBA-PD患者从仰卧位转变为直立位时收缩压下降得更明显

葡萄糖苷酶(GBA)基因的变异是帕金森病(PD)发病最常见的遗传风险因素。在一项包括1,360名参与者的大型国际综合基因筛查研究中,8.5%的帕金森病患者被发现携带杂合的GBA变体,其中最常见的是c.1093G>A(p.Glu365Lys,也称为E326K)和c.1223C>T(p.Thr408Met,也称为T369M)。在最近的一项荟萃分析中发现,这两个变异体在非阿什肯纳齐犹太人群中显著增加PD的风险。

图1:论文封面图

直立性低血压(OH)被定义为在站立3分钟内收缩压持续下降至少20毫米汞柱或舒张压下降10毫米汞柱。在PD中,OH的发生率为30-40%,取决于病程和疾病的严重程度。与GBA相关的PD(GBA-PD)患者报告自律神经症状,如OH,比特发性PD(IPD)患者更频繁,程度更严重。

与这些报告相反,一项针对1435名PD患者的大型国际研究和最近的荟萃分析没有发现GBA-PD和IPD患者之间有不同的OH频率;然而,仍然不能确定如何评估OH。

OH与认知能力下降以及姿势不稳和步态困难表型(PIGD)有关。这些临床特征在GBA-PD中也比IPD中更常见。PD中的OH主要是由于心血管症状神经支配导致的肾上腺素缺乏的结果。

以前的一份报告发现,与IPD相比,GBA-PD的心肌(123)I-metaiodo-benzylguanidine摄取量有更大的减少,这表明GBA-PD的交感神经失调更为明显。

为了解决GBA-PD与IPD相比在OH发生率方面的矛盾,德国University of Lubeck的Tatiana Usnich等人,在以前描述的和同时扩大的PD队列中进行了OH分析。他们旨在评估GBA-PD与IPD相比,从仰卧位转为直立位时的血压变化,并捕捉在改变体位时发生的任何相关症状。

与特发性帕金森病患者(IPD)相比,携带葡萄糖脑苷脂酶(GBA)基因变体的帕金森病患者(GBA-PD)更频繁地出现正压症状。

他们对33名GBA-PD和313名IPD患者进行了前瞻性分析。

与IPD患者相比,GBA-PD患者从仰卧位转变为直立位时收缩压下降得更明显

图2:论文结果图

舒张压和心率在组间没有差异。

这项研究为GBA-PD中自律神经系统的明显参与提供了进一步证据。


原文出处:
on behalf of the EPIPARK Study Group, Usnich T, Hanssen H, et al. Pronounced Orthostatic Hypotension in GBA-Related Parkinson’s Disease. JPD. Published online April 28, 2022:1-6. doi:10.3233/JPD-223197

 

评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1239913, encodeId=e0001239913a1, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff9c3032606, createdName=laiminchao, createdTime=Sat Aug 20 08:07:25 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757452, encodeId=f7421e57452f8, content=<a href='/topic/show?id=058e4852e63' target=_blank style='color:#2F92EE;'>#帕金森病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48527, encryptionId=058e4852e63, topicName=帕金森病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a17f37322741, createdName=ms6832696159214430, createdTime=Sat Apr 15 08:51:20 CST 2023, time=2023-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1367433, encodeId=357e136e433cf, content=<a href='/topic/show?id=f4012634656' target=_blank style='color:#2F92EE;'>#低血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26346, encryptionId=f4012634656, topicName=低血压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Fri May 20 05:51:20 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573965, encodeId=7b7415e39654f, content=<a href='/topic/show?id=6b3348526a0' target=_blank style='color:#2F92EE;'>#帕金森病患#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48526, encryptionId=6b3348526a0, topicName=帕金森病患)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri May 20 05:51:20 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1220934, encodeId=c1c312209344b, content=111, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43958165571, createdName=ms9000000795072041, createdTime=Thu May 19 14:51:39 CST 2022, time=2022-05-19, status=1, ipAttribution=)]
    2022-08-20 laiminchao

    感谢分享

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1239913, encodeId=e0001239913a1, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff9c3032606, createdName=laiminchao, createdTime=Sat Aug 20 08:07:25 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757452, encodeId=f7421e57452f8, content=<a href='/topic/show?id=058e4852e63' target=_blank style='color:#2F92EE;'>#帕金森病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48527, encryptionId=058e4852e63, topicName=帕金森病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a17f37322741, createdName=ms6832696159214430, createdTime=Sat Apr 15 08:51:20 CST 2023, time=2023-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1367433, encodeId=357e136e433cf, content=<a href='/topic/show?id=f4012634656' target=_blank style='color:#2F92EE;'>#低血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26346, encryptionId=f4012634656, topicName=低血压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Fri May 20 05:51:20 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573965, encodeId=7b7415e39654f, content=<a href='/topic/show?id=6b3348526a0' target=_blank style='color:#2F92EE;'>#帕金森病患#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48526, encryptionId=6b3348526a0, topicName=帕金森病患)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri May 20 05:51:20 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1220934, encodeId=c1c312209344b, content=111, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43958165571, createdName=ms9000000795072041, createdTime=Thu May 19 14:51:39 CST 2022, time=2022-05-19, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1239913, encodeId=e0001239913a1, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff9c3032606, createdName=laiminchao, createdTime=Sat Aug 20 08:07:25 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757452, encodeId=f7421e57452f8, content=<a href='/topic/show?id=058e4852e63' target=_blank style='color:#2F92EE;'>#帕金森病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48527, encryptionId=058e4852e63, topicName=帕金森病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a17f37322741, createdName=ms6832696159214430, createdTime=Sat Apr 15 08:51:20 CST 2023, time=2023-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1367433, encodeId=357e136e433cf, content=<a href='/topic/show?id=f4012634656' target=_blank style='color:#2F92EE;'>#低血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26346, encryptionId=f4012634656, topicName=低血压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Fri May 20 05:51:20 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573965, encodeId=7b7415e39654f, content=<a href='/topic/show?id=6b3348526a0' target=_blank style='color:#2F92EE;'>#帕金森病患#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48526, encryptionId=6b3348526a0, topicName=帕金森病患)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri May 20 05:51:20 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1220934, encodeId=c1c312209344b, content=111, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43958165571, createdName=ms9000000795072041, createdTime=Thu May 19 14:51:39 CST 2022, time=2022-05-19, status=1, ipAttribution=)]
    2022-05-20 chentianping

    #低血压#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1239913, encodeId=e0001239913a1, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff9c3032606, createdName=laiminchao, createdTime=Sat Aug 20 08:07:25 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757452, encodeId=f7421e57452f8, content=<a href='/topic/show?id=058e4852e63' target=_blank style='color:#2F92EE;'>#帕金森病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48527, encryptionId=058e4852e63, topicName=帕金森病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a17f37322741, createdName=ms6832696159214430, createdTime=Sat Apr 15 08:51:20 CST 2023, time=2023-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1367433, encodeId=357e136e433cf, content=<a href='/topic/show?id=f4012634656' target=_blank style='color:#2F92EE;'>#低血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26346, encryptionId=f4012634656, topicName=低血压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Fri May 20 05:51:20 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573965, encodeId=7b7415e39654f, content=<a href='/topic/show?id=6b3348526a0' target=_blank style='color:#2F92EE;'>#帕金森病患#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48526, encryptionId=6b3348526a0, topicName=帕金森病患)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri May 20 05:51:20 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1220934, encodeId=c1c312209344b, content=111, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43958165571, createdName=ms9000000795072041, createdTime=Thu May 19 14:51:39 CST 2022, time=2022-05-19, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1239913, encodeId=e0001239913a1, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff9c3032606, createdName=laiminchao, createdTime=Sat Aug 20 08:07:25 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757452, encodeId=f7421e57452f8, content=<a href='/topic/show?id=058e4852e63' target=_blank style='color:#2F92EE;'>#帕金森病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48527, encryptionId=058e4852e63, topicName=帕金森病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a17f37322741, createdName=ms6832696159214430, createdTime=Sat Apr 15 08:51:20 CST 2023, time=2023-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1367433, encodeId=357e136e433cf, content=<a href='/topic/show?id=f4012634656' target=_blank style='color:#2F92EE;'>#低血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26346, encryptionId=f4012634656, topicName=低血压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Fri May 20 05:51:20 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573965, encodeId=7b7415e39654f, content=<a href='/topic/show?id=6b3348526a0' target=_blank style='color:#2F92EE;'>#帕金森病患#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48526, encryptionId=6b3348526a0, topicName=帕金森病患)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri May 20 05:51:20 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1220934, encodeId=c1c312209344b, content=111, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43958165571, createdName=ms9000000795072041, createdTime=Thu May 19 14:51:39 CST 2022, time=2022-05-19, status=1, ipAttribution=)]
    2022-05-19 ms9000000795072041

    111

    3

    展开3条回复

相关资讯

JPD:低频率的前庭噪音刺激,或可改善帕金森患者姿势障碍

在接受低强度nGVS治疗的患者中,至少有一半的患者在姿势平衡方面表现出与SR相符的有力改善

JPD:冷漠反映了新发帕金森病的纹状体外多巴胺能变性

孤立的帕金森病患者与纹状体外多巴胺能变性有关。

Neurology:神经丝光与帕金森病的发展和严重程度的关联

血液生物标记物可能有助于早期识别帕金森氏病(PD)、帕金森氏症及PD相关不良结局。近日,研究人员发现Nf-L与临床帕金森病、帕金森症状和身体功能下降有关。Nf-L或为神经退行性变潜在生物标记物。

JPD:人格测试,有助于帕金森病基本分类

早期帕金森病患者的性格使我们能够识别3种患者的表型

JPD:帕金森患者的抑郁发病情况如何?

帕金森患者的患病率多少?

拓展阅读

帕金森病:body-first 与 brain-first之辨

帕金森病的体优先和脑优先假说为理解这种复杂疾病的异质性提供了有价值的框架。

论文解读|魏建设/乔军波教授团队揭示线粒体功能障碍及衰老与帕金森病密切相关

该研究系统揭示了线粒体功能失衡、衰老及胶质细胞异常在PD中的交互作用机制,为理解PD病理进程提供了新视角。

帕金森前沿洞察:防治新知全解锁

无论你是想拓宽知识面,还是提升诊疗能力,这份资料都别错过!

BMJ:全球帕金森病流行趋势预测:2050年患者人数将翻番,老龄化成增长主因

预计到2050年,全球帕金森病患者将达到2520万人,较2021年增长112%,疾病负担显著上升。

中药复方鼎真丸的现代药理突破!Chinese Medicine发文:鼎真丸抑制cGAS-STING通路减轻帕金森病神经铁死亡

本研究首次系统揭示了传统中药方剂“鼎真丸”(DZP)通过抑制cGAS-STING通路,减轻帕金森病(PD)模型小鼠神经元的铁死亡与神经炎症。

帕金森病经颅超声检查中国指南

中国医师协会超声医师分会 · 2025-02-20

2025 BAN共识指南:帕金森病的管理-第II部分:非运动症状

巴西神经病学学会(BAN,Brazilian Academy of Neurology) · 2025-01-31

中国经颅超声检查帕金森病规范与诊断指南

中国医师协会超声医师分会 · 2025-02-14